Journal of Clinical Oncology, Vol 14, 35-45, Copyright © 1996 by American Society of Clinical Oncology
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group
RC Coombes, JM Bliss, J Wils, F Morvan, M Espie, D Amadori, P Gambrosier, M Richards, M Aapro, A Villar-Grimalt, C McArdle, FR Perez-Lopez, P Vassilopoulos, EP Ferreira, CE Chilvers, G Coombes, EM Woods and M Marty
Medical Oncology Unit, Charing Cross Hospital, United Kingdom.
PURPOSE: To determine whether a combination chemotherapy regimen that
contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC])
is superior to the standard cyclophosphamide, methotrexate, and
fluorouracil (CMF) combination in premenopausal women with axillary
node-positive operable breast cancer. PATIENTS AND METHODS: The
International Collaborative Cancer Group (ICCG) conducted a large
randomized trial in which two alternative schedules were used according to
participating center: CMF1 versus FEC1 and CMF2 versus FEC2. RESULTS: Seven
hundred fifty-nine patients were entered onto the trial. At a median
follow-up time of 4.5 years, no significant benefit for the
anthracycline-containing regimen was observed in terms of relapse-free (P =
.61) or overall survival (P = .13). FEC1 and CMF1 appear to be of similar
efficacy, but there is a suggestion that FEC2 may be superior to CMF2,
since patients who received FEC2 had improved overall (P = .02) and
relapse-free survival (P = .03) rates. Nausea and vomiting and alopecia
were more common in the epirubicin-containing regimen (P = .001).
CONCLUSION: We conclude that the FEC2 regimen, in which epirubicin replaced
the methotrexate in CMF, is the preferable adjuvant chemotherapy regimen
for premenopausal patients with operable axillary node-positive breast
cancer.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
K. TAGUCHI, H. IIHARA, M. ISHIHARA, Y. KOMORI, K. TANIZAWA, K. MATSUURA, and Y. ITOH
Comparison of Antiemetic Efficacy between Single and Repeated Treatments with a 5-HT3 Receptor Antagonist in Breast Cancer Patients with High-risk Emetogenic Chemotherapy
Anticancer Res,
May 1, 2009;
29(5):
1721 - 1725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Poole, H. M. Earl, L. Hiller, J. A. Dunn, S. Bathers, R. J. Grieve, D. A. Spooner, R. K. Agrawal, I. N. Fernando, A. M. Brunt, et al.
Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer
N. Engl. J. Med.,
November 2, 2006;
355(18):
1851 - 1862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lohrisch, C. Paltiel, K. Gelmon, C. Speers, S. Taylor, J. Barnett, and I. A. Olivotto
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
J. Clin. Oncol.,
October 20, 2006;
24(30):
4888 - 4894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Nilsson, and J. Bergh
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
J. Clin. Oncol.,
June 1, 2006;
24(16):
2428 - 2436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Oncologist,
February 1, 2006;
11(2):
111 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Hutchins, S. J. Green, P. M. Ravdin, D. Lew, S. Martino, M. Abeloff, A. P. Lyss, C. Allred, S. E. Rivkin, and C. K. Osborne
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
J. Clin. Oncol.,
November 20, 2005;
23(33):
8313 - 8321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gluck
Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin
Oncologist,
November 1, 2005;
10(10):
780 - 791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Campone, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al.
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group
Ann. Onc.,
August 1, 2005;
16(8):
1343 - 1351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Praga, J. Bergh, J. Bliss, J. Bonneterre, B. Cesana, R. C. Coombes, P. Fargeot, A. Folin, P. Fumoleau, R. Giuliani, et al.
Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide
J. Clin. Oncol.,
June 20, 2005;
23(18):
4179 - 4191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bonneterre, H. Roche, P. Kerbrat, A. Bremond, P. Fumoleau, M. Namer, M.-J. Goudier, S. Schraub, P. Fargeot, and I. Chapelle-Marcillac
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
J. Clin. Oncol.,
April 20, 2005;
23(12):
2686 - 2693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol.,
March 10, 2005;
23(8):
1760 - 1775.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Papaldo, M. Lopez, E. Cortesi, E. Cammilluzzi, M. Antimi, E. Terzoli, G. Lepidini, P. Vici, C. Barone, G. Ferretti, et al.
Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide
J. Clin. Oncol.,
September 15, 2003;
21(18):
3462 - 3468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Samur and H. S. Bozcuk
Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients? Not Yet!
J. Clin. Oncol.,
June 15, 2003;
21(12):
2444 - 2444.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Martin, A. Villar, A. Sole-Calvo, R. Gonzalez, B. Massuti, J. Lizon, C. Camps, A. Carrato, A. Casado, M. T. Candel, et al.
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group
Ann. Onc.,
June 1, 2003;
14(6):
833 - 842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bernard-Marty, M. Mano, M. Paesmans, C. Accettura, R. Munoz-Bermeo, T. Richard, K. Kleiber, F. Cardoso, J. P. Lobelle, D. Larsimont, et al.
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients
Ann. Onc.,
May 1, 2003;
14(5):
693 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Pritchard
Adjuvant Therapy for Premenopausal Women With Breast Cancer: Is It Time for Another Paradigm Shift?
J. Clin. Oncol.,
December 15, 2002;
20(24):
4611 - 4614.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. N Hortobagyi
Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview
J Natl Cancer Inst Monographs,
December 1, 2001;
2001(30):
72 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Paradiso, F. Schittulli, G. Cellamare, A. Mangia, F. Marzullo, V. Lorusso, and M. De Lena
Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer
J. Clin. Oncol.,
October 1, 2001;
19(19):
3929 - 3937.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. J. Piccart, A. Di Leo, M. Beauduin, A. Vindevoghel, J. Michel, C. Focan, A. Tagnon, F. Ries, P. Gobert, C. Finet, et al.
Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer
J. Clin. Oncol.,
June 15, 2001;
19(12):
3103 - 3110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial
J. Clin. Oncol.,
February 1, 2001;
19(3):
602 - 611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.A. Wils, J.M. Bliss, M. Marty, G. Coombes, C. Fontaine, F. Morvan, T. Olmos, F.R. Perez-Lopez, P. Vassilopoulos, E. Woods, et al.
Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group
J. Clin. Oncol.,
July 1, 1999;
17(7):
1988 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hudis, A. Seidman, J. Baselga, G. Raptis, D. Lebwohl, T. Gilewski, M. Moynahan, N. Sklarin, D. Fennelly, J. P.A. Crown, et al.
Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy
J. Clin. Oncol.,
January 1, 1999;
17(1):
93 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ray-Coquard, T. Philip, M. Lehmann, B. Fervers, F. Farsi, and F. Chauvin
Impact of a Clinical Guidelines Program for Breast and Colon Cancer in a French Cancer Center
JAMA,
November 19, 1997;
278(19):
1591 - 1595.
[Abstract]
[PDF]
|
|
|
|
